2183-56-4

Basic information

• Product Name: hydromorphinol
• Synonyms: hydromorphinol;(5a,6a)-4,5-Epoxy-17-methylmorphinan-3,6,14-triol;14-Hydroxy-7,8-dihydromorphine;6a-Oxymorphol;7,8-Dihydro-14-hydroxymorphine;a-Oxymorphol;14-Hydroxydihydromorphine;Oxymorphol
• CAS NO: 2183-56-4
• Molecular Formula: C₁₇H₂₁NO₄
• Molecular Weight: 303.356
• EINECS: 218-565-9
• Product Categories: Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 2183-56-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 252-253 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 517.6°Cat760mmHg
• Flash Point: 266.8°C
• Appearance: /
• Density: 1.5g/cm³
• Vapor Pressure: 1.53E-11mmHg at 25°C
• Refractive Index: 1.721
• PKA: 9.39±0.60(Predicted)
• CAS DataBase Reference: hydromorphinol(CAS DataBase Reference)
• NIST Chemistry Reference: hydromorphinol(2183-56-4)
• EPA Substance Registry System: hydromorphinol(2183-56-4)

Safety Data

• Hazardous Substances Data: 2183-56-4(Hazardous Substances Data)

Usage

Description

Hydromorphinol, also known as 6α-Oxymorphol (CRM), is a certified reference material categorized as an opioid. It is a metabolite of oxymorphone and is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.

Uses

Used in Pharmaceutical Industry:
Hydromorphinol is used as an active pharmaceutical ingredient for the development of pain relief medications. It is derived from oxymorphone, which is known for its potent analgesic properties, making it a valuable compound in the creation of effective pain management drugs.
Used in Research and Forensic Applications:
Hydromorphinol is used as a reference material in research and forensic applications. Its status as a Schedule I compound in the United States highlights its importance in the study of opioid compounds and their effects on the human body. This application aids in understanding the pharmacological properties of opioids and their potential for misuse, as well as in the development of detection methods for these substances in forensic investigations.
Brand Name:
Hydromorphinol is marketed under the brand name Ifex by Bristol-Myers Squibb, where it is utilized for its pain-relieving properties in medical treatments.

InChI:InChI=1/C17H21NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,11-12,15,19-21H,4-8H2,1H3/t11-,12+,15-,16-,17+/m0/s1

Upstream product

• 7183-69-9 14-hydroxydihydrocodeine 
• 50-00-0 formaldehyd 
• 33522-95-1 noroxymorphone 
• 76-41-5 oxymorphone 
• 4829-46-3 14-hydroxycodeine 

Downstream Products

• 72782-04-8 6β-oxymorphamine 

Relevant articles and documents

PROCESS FOR MAKING MORPHINAN-6alpha-OLS

The present invention provides a process whereby morphinan-6-ones can be converted stereospecifically to the corresponding morphinan-6α-ols by catalytic hydrogenation under basic conditions.

Probes for narcotic receptor mediated phenomena. 24. synthesis, single crystal X-ray analyses, in vitro and in vivo properties of 6α-and 6β-IODO-3,14-dihydroxy-17-methyl-4,5α-epoxymorphinans

The 6α- and 6β-iodo-3,14-dihydroxy-17-methyl-4,5α-epoxymorphinans, potential SPECT ligands, were synthesized and found to be μ-selective opioids, more potent in vitro and in vivo than their 6-hydroxy relatives. Single-crystal analysis showed that the 6α- and 6β-iodine atoms are spatially closely located although the C-ring conformations of these compounds are quite different (twist-boat form vs. chair). These epimeric conformational differences were not reflected in their binding affinities.

Synthesis and utilization of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy 6β-fluoromorphinans (foxy and cyclofoxy) as (18F)-labeled opioid ligands for position emission transaxial tomography (PETT)

Fluorinated derivatives 3,14-dihydroxy-4,5α-epoxy-6β-fluoro-17-methylmorphinan (""fluorooxymorphone""; FOXY, compound 10) and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy-6β-fluoromorphinan (CYCLOFOXY, compound 18) are prepared based upon the structures of the potent opioid agonist oxymorphone 4 and the antagonist naltrexone 11, respectively. Fluorine was introduced in the final stages of synthesis by a facile nucleophilic displacement with fluoride ion of the 6α-triflate functions in 8 and 16. The synthetic procedures were suitable for the production of the corresponding positron emitting 18 F-labeled analogs 18 F-FOXY and 18 F-CYCLOFOXY, which are useful for in vivo studies of the opioid receptor system using positron emission transaxial tomography. In addition, the tritiation of FOXY (10) to high specific activity is noted.